Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Brown, W.V
Right arrow Search for Related Content
PubMed
Right arrow Articles by Brown, W.V
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

The European Society of Cardiology

Managing dyslipidaemia – multiple patients and multiple approaches: metabolic syndrome, familial hypercholesterolaemia and hypertension

W.V Brown*

Emory University, Atlanta, GA, USA

* W. Virgil Brown, MD, Charles Howard Chandler Professor of Internal Medicine, Director of the Division of Arteriosclerosis and Lipid Metabolism, Emory University School of Medicine, Woodruff Memorial Building, Bldg. A, 1365 Clifton Road, NE, Atlanta, GA 30322, USA. Tel.: +1-404-235-3001
w.virgil.brown{at}med.va.gov

Abstract

High risk of coronary heart disease (CHD) events is present in a number of patient populations in addition to those with pre-existing CHD, other atherosclerotic disease or diabetes. Patients with the metabolic syndrome are at increased CHD risk and require attention to low-density lipoprotein cholesterol (LDL-C) lowering in addition to management of hypertriglyceridaemia, low high-density lipoprotein cholesterol and non-lipid risk factors. Patients with hypertension in addition to other cardiovascular risk factors are at increased risk of CHD and have recently been shown to derive marked benefit from statin treatment. Patients with heterozygous familial hypercholesterolaemia, characterised by dramatically raised LDL-C and high risk for early CHD, require large reductions in LDL-C to meet recommended target levels, and newer statins possess the LDL-C-lowering efficacy to bring many of these patients to such goals. Identification of high-risk patients and prompt institution of appropriate management strategies can serve to reduce the overall burden of cardiovascular disease.

Key Words: Dyslipidaemia • Metabolic syndrome • Familial hypercholesterolaemia • Statins • Coronary heart disease • LDL cholesterol


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.